A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

In fact, Novo Nordisk, the manufacturer of Ozempic, announced plans to study whether or not the drug can impact someone’s ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...